文献速递血脂与心血管预防冠心病心力衰竭与心肌病

GLP-1受体激动剂与DPP-4抑制剂的心血管作用及临床结局

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
PubMed 文献 · Circulation · 2017-01-01

本文综述了GLP-1受体激动剂和DPP-4抑制剂的心血管作用机制及临床结局试验。利拉鲁肽(LEADER)和索马鲁肽(SUSTAIN-6)显著降低2型糖尿病高危患者首次主要不良心血管事件时间,分别减少13%和24%;而利西拉来(ELIXA)及DPP-4抑制剂(SAVOR-TIMI 53、EXAMINE、TECOS)既不增加也不减少心血管事件。

要点

  • 利拉鲁肽和索马鲁肽可显著降低2型糖尿病高危患者主要心血管不良事件风险。
  • 利西拉来及沙格列汀、阿格列汀、西格列汀对心血管事件呈中性影响。
  • 需进一步明确GLP-1R激动剂心血管获益的潜在机制及不确定性领域。

核心结论

  • GLP-1R激动剂利拉鲁肽和索马鲁肽可显著减少2型糖尿病高危患者首次主要不良心血管事件时间,而利西拉来及DPP-4抑制剂对心血管事件呈中性影响。

研究设计与样本

  • 本文为综述,聚焦于将临床前研究机制转化为临床研究互补发现,未报告系统检索范围。

主要发现

  • LEADER试验显示利拉鲁肽使首次主要不良心血管事件时间显著减少13%。
  • SUSTAIN-6试验显示索马鲁肽使首次主要不良心血管事件时间显著减少24%。
  • ELIXA试验显示利西拉来既不增加也不减少心血管事件。
  • SAVOR-TIMI 53、EXAMINE和TECOS试验显示沙格列汀、阿格列汀和西格列汀既不增加也不减少心血管事件。
  • 临床前研究提示GLP-1R激动剂和DPP-4抑制剂在心肌缺血和心室功能障碍动物模型中通过不完全明确的机制发挥心脏保护作用。

临床怎么用

  • 对于2型糖尿病合并心血管高危患者,可优先考虑具有心血管获益证据的GLP-1R激动剂如利拉鲁肽和索马鲁肽。

局限性

  • GLP-1R激动剂和DPP-4抑制剂心脏保护作用的机制尚未完全阐明,存在不确定性领域需进一步基础与临床研究审视。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor (GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl peptidase-4 (DPP-4) promotes glycemic reduction for the treatment of type 2 diabetes mellitus by glucose-dependent control of insulin and glucagon secretion. GLP-1R agonists also decelerate gastric emptying, reduce body weight by reduction of food intake and lower circulating lipoproteins, inflammation, and systolic blood pressure. Preclinical studies demonstrate that both GLP-1R agonists and DPP-4 inhibitors exhibit cardioprotective actions in animal models of myocardial ischemia and ventricular dysfunction through incompletely characterized mechanisms. The results of cardiovascular outcome trials in human subjects with type 2 diabetes mellitus and increased cardiovascular risk have demonstrated a cardiovascular benefit (significant reduction in time to first major adverse cardiovascular event) with the GLP-1R agonists liraglutide (LEADER trial [Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Ourcome Results], -13%) and semaglutide (SUSTAIN-6 trial [Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide], -24%). In contrast, cardiovascular outcome trials examining the safety of the shorter-acting GLP-1R agonist lixisenatide (ELIXA trial [Evaluation of Lixisenatide in Acute Coronary Syndrom]) and the DPP-4 inhibitors saxagliptin (SAVOR-TIMI 53 trial [Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53]), alogliptin (EXAMINE trial [Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome]), and sitagliptin (TECOS [Trial Evaluating Cardiovascular Outcomes With Sitagliptin]) found that these agents neither increased nor decreased cardiovascular events. Here we review the cardiovascular actions of GLP-1R agonists and DPP-4 inhibitors, with a focus on the translation of mechanisms derived from preclinical studies to complementary findings in clinical studies. We highlight areas of uncertainty requiring more careful scrutiny in ongoing basic science and clinical studies. As newer more potent GLP-1R agonists and coagonists are being developed for the treatment of type 2 diabetes mellitus, obesity, and nonalcoholic steatohepatitis, the delineation of the potential mechanisms that underlie the cardiovascular benefit and safety of these agents have immediate relevance for the prevention and treatment of cardiovascular disease.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017. PMID: 28847797. doi:10.1161/CIRCULATIONAHA.117.028136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。